Invention Grant
- Patent Title: Crystalline hydrate of a JAK inhibitor compound
-
Application No.: US17249375Application Date: 2021-03-01
-
Publication No.: US11702415B2Publication Date: 2023-07-18
- Inventor: Gene Timothy Fass
- Applicant: THERAVANCE BIOPHARMA R&D IP, LLC
- Applicant Address: US CA South San Francisco
- Assignee: Theravance Biopharma R&D IP, LLC
- Current Assignee: Theravance Biopharma R&D IP, LLC
- Current Assignee Address: US CA South San Francisco
- Agency: Sheppard Mullin Richter & Hampton LLP
- Main IPC: C07D471/04
- IPC: C07D471/04 ; A61P11/06 ; A61K9/00
Abstract:
Provided herein is a crystalline hydrate of the compound of formula 1:
Also provides herein are pharmaceutical compositions comprising such crystalline hydrate, methods of using such crystalline hydrate to treat respiratory diseases, and processes useful for preparing such crystalline hydrate.
Also provides herein are pharmaceutical compositions comprising such crystalline hydrate, methods of using such crystalline hydrate to treat respiratory diseases, and processes useful for preparing such crystalline hydrate.
Public/Granted literature
- US20210269437A1 CRYSTALLINE HYDRATE OF A JAK INHIBITOR COMPOUND Public/Granted day:2021-09-02
Information query
